Ozempic maker defends high U.S. price: It’s ‘helping’ reduce the cost of obesity
As a healthcare professional, I have always been appalled by the exorbitant prices that pharmaceutical companies charge for life-saving medications in the United States. The recent controversy surrounding Novo Nordisk’s pricing of Ozempic and Wegovy sheds light on the profit-driven motives that underlie the pharmaceutical industry. It is truly disheartening to see medications that could potentially improve the health and well-being of individuals being priced out of reach for many Americans.
Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, has defended the high U.S. prices of these drugs by claiming that they are ‘helping’ reduce the cost of obesity in the long run.… Continue reading
John Q. Hosedrinker